Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers

Autores
Muraca, Giuliana Sabrina; Rivero Berti, Ignacio; Sbaraglini, Maria Laura; Fávaro, Wagner J.; Durán, Nelson; Castro, Guillermo Raul; Talevi, Alan
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Trypanosomatid-caused conditions (African trypanosomiasis, Chagas disease, and leishmaniasis) are neglected tropical infectious diseases that mainly affect socioeconomically vulnerable populations. The available therapeutics display substantial limitations, among them limited efficacy, safety issues, drug resistance, and, in some cases, inconvenient routes of administration, which made the scenarios with insufficient health infrastructure settings inconvenient. Pharmaceutical nanocarriers may provide solutions to some of these obstacles, improving the efficacy–safety balance and tolerability to therapeutic interventions. Here, we overview the state of the art of therapeutics for trypanosomatid-caused diseases (including approved drugs and drugs undergoing clinical trials) and the literature on nanolipid pharmaceutical carriers encapsulating approved and non-approved drugs for these diseases. Numerous studies have focused on the obtention and preclinical assessment of lipid nanocarriers, particularly those addressing the two currently most challenging trypanosomatid-caused diseases, Chagas disease, and leishmaniasis. In general, in vitro and in vivo studies suggest that delivering the drugs using such type of nanocarriers could improve the efficacy–safety balance, diminishing cytotoxicity and organ toxicity, especially in leishmaniasis. This constitutes a very relevant outcome, as it opens the possibility to extended treatment regimens and improved compliance. Despite these advances, last-generation nanosystems, such as targeted nanocarriers and hybrid systems, have still not been extensively explored in the field of trypanosomatid-caused conditions and represent promising opportunities for future developments. The potential use of nanotechnology in extended, well-tolerated drug regimens is particularly interesting in the light of recent descriptions of quiescent/dormant stages of Leishmania and Trypanosoma cruzi, which have been linked to therapeutic failure.
Fil: Muraca, Giuliana Sabrina. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Ministerio de Salud. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica; Argentina
Fil: Rivero Berti, Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Investigación y Desarrollo en Fermentaciones Industriales. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Investigación y Desarrollo en Fermentaciones Industriales; Argentina
Fil: Sbaraglini, Maria Laura. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
Fil: Fávaro, Wagner J.. Universidade Estadual Do Campinas. Instituto de Biologia. Departamento de Biologia Estructural y Funcional.; Brasil
Fil: Durán, Nelson. Universidade Estadual Do Campinas. Instituto de Biologia. Departamento de Biologia Estructural y Funcional.; Brasil. Universidad Federal do Abc; Brasil
Fil: Castro, Guillermo Raul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Investigación y Desarrollo en Fermentaciones Industriales. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Investigación y Desarrollo en Fermentaciones Industriales; Argentina
Fil: Talevi, Alan. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
Materia
CHAGAS
HUMAN AFRICAN TRYPANOSOMIASIS
LEISHMANIASIS
LIPID NANOPARTICLES
LIPOSOMES
NANOESTRUCTED LIPID CARRIER
NANOPARTICLE
SOLID LIPID NANO PARTICLES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/143293
Acceder
id CONICETDig_1142284394c71e27c4dc63c31bf3aa68
oai_identifier_str oai:ri.conicet.gov.ar:11336/143293
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriersMuraca, Giuliana SabrinaRivero Berti, IgnacioSbaraglini, Maria LauraFávaro, Wagner J.Durán, NelsonCastro, Guillermo RaulTalevi, AlanCHAGASHUMAN AFRICAN TRYPANOSOMIASISLEISHMANIASISLIPID NANOPARTICLESLIPOSOMESNANOESTRUCTED LIPID CARRIERNANOPARTICLESOLID LIPID NANO PARTICLEShttps://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3Trypanosomatid-caused conditions (African trypanosomiasis, Chagas disease, and leishmaniasis) are neglected tropical infectious diseases that mainly affect socioeconomically vulnerable populations. The available therapeutics display substantial limitations, among them limited efficacy, safety issues, drug resistance, and, in some cases, inconvenient routes of administration, which made the scenarios with insufficient health infrastructure settings inconvenient. Pharmaceutical nanocarriers may provide solutions to some of these obstacles, improving the efficacy–safety balance and tolerability to therapeutic interventions. Here, we overview the state of the art of therapeutics for trypanosomatid-caused diseases (including approved drugs and drugs undergoing clinical trials) and the literature on nanolipid pharmaceutical carriers encapsulating approved and non-approved drugs for these diseases. Numerous studies have focused on the obtention and preclinical assessment of lipid nanocarriers, particularly those addressing the two currently most challenging trypanosomatid-caused diseases, Chagas disease, and leishmaniasis. In general, in vitro and in vivo studies suggest that delivering the drugs using such type of nanocarriers could improve the efficacy–safety balance, diminishing cytotoxicity and organ toxicity, especially in leishmaniasis. This constitutes a very relevant outcome, as it opens the possibility to extended treatment regimens and improved compliance. Despite these advances, last-generation nanosystems, such as targeted nanocarriers and hybrid systems, have still not been extensively explored in the field of trypanosomatid-caused conditions and represent promising opportunities for future developments. The potential use of nanotechnology in extended, well-tolerated drug regimens is particularly interesting in the light of recent descriptions of quiescent/dormant stages of Leishmania and Trypanosoma cruzi, which have been linked to therapeutic failure.Fil: Muraca, Giuliana Sabrina. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Ministerio de Salud. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica; ArgentinaFil: Rivero Berti, Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Investigación y Desarrollo en Fermentaciones Industriales. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Investigación y Desarrollo en Fermentaciones Industriales; ArgentinaFil: Sbaraglini, Maria Laura. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; ArgentinaFil: Fávaro, Wagner J.. Universidade Estadual Do Campinas. Instituto de Biologia. Departamento de Biologia Estructural y Funcional.; BrasilFil: Durán, Nelson. Universidade Estadual Do Campinas. Instituto de Biologia. Departamento de Biologia Estructural y Funcional.; Brasil. Universidad Federal do Abc; BrasilFil: Castro, Guillermo Raul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Investigación y Desarrollo en Fermentaciones Industriales. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Investigación y Desarrollo en Fermentaciones Industriales; ArgentinaFil: Talevi, Alan. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; ArgentinaFrontiers Media2020-11-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/143293Muraca, Giuliana Sabrina; Rivero Berti, Ignacio; Sbaraglini, Maria Laura; Fávaro, Wagner J.; Durán, Nelson; et al.; Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers; Frontiers Media; Frontiers in Chemistry; 8; 26-11-2020; 1-232296-2646CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fchem.2020.601151/fullinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fchem.2020.601151info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:06:59Zoai:ri.conicet.gov.ar:11336/143293instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:06:59.633CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers
title Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers
spellingShingle Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers
Muraca, Giuliana Sabrina
CHAGAS
HUMAN AFRICAN TRYPANOSOMIASIS
LEISHMANIASIS
LIPID NANOPARTICLES
LIPOSOMES
NANOESTRUCTED LIPID CARRIER
NANOPARTICLE
SOLID LIPID NANO PARTICLES
title_short Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers
title_full Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers
title_fullStr Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers
title_full_unstemmed Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers
title_sort Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers
dc.creator.none.fl_str_mv Muraca, Giuliana Sabrina
Rivero Berti, Ignacio
Sbaraglini, Maria Laura
Fávaro, Wagner J.
Durán, Nelson
Castro, Guillermo Raul
Talevi, Alan
author Muraca, Giuliana Sabrina
author_facet Muraca, Giuliana Sabrina
Rivero Berti, Ignacio
Sbaraglini, Maria Laura
Fávaro, Wagner J.
Durán, Nelson
Castro, Guillermo Raul
Talevi, Alan
author_role author
author2 Rivero Berti, Ignacio
Sbaraglini, Maria Laura
Fávaro, Wagner J.
Durán, Nelson
Castro, Guillermo Raul
Talevi, Alan
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv CHAGAS
HUMAN AFRICAN TRYPANOSOMIASIS
LEISHMANIASIS
LIPID NANOPARTICLES
LIPOSOMES
NANOESTRUCTED LIPID CARRIER
NANOPARTICLE
SOLID LIPID NANO PARTICLES
topic CHAGAS
HUMAN AFRICAN TRYPANOSOMIASIS
LEISHMANIASIS
LIPID NANOPARTICLES
LIPOSOMES
NANOESTRUCTED LIPID CARRIER
NANOPARTICLE
SOLID LIPID NANO PARTICLES
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.4
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Trypanosomatid-caused conditions (African trypanosomiasis, Chagas disease, and leishmaniasis) are neglected tropical infectious diseases that mainly affect socioeconomically vulnerable populations. The available therapeutics display substantial limitations, among them limited efficacy, safety issues, drug resistance, and, in some cases, inconvenient routes of administration, which made the scenarios with insufficient health infrastructure settings inconvenient. Pharmaceutical nanocarriers may provide solutions to some of these obstacles, improving the efficacy–safety balance and tolerability to therapeutic interventions. Here, we overview the state of the art of therapeutics for trypanosomatid-caused diseases (including approved drugs and drugs undergoing clinical trials) and the literature on nanolipid pharmaceutical carriers encapsulating approved and non-approved drugs for these diseases. Numerous studies have focused on the obtention and preclinical assessment of lipid nanocarriers, particularly those addressing the two currently most challenging trypanosomatid-caused diseases, Chagas disease, and leishmaniasis. In general, in vitro and in vivo studies suggest that delivering the drugs using such type of nanocarriers could improve the efficacy–safety balance, diminishing cytotoxicity and organ toxicity, especially in leishmaniasis. This constitutes a very relevant outcome, as it opens the possibility to extended treatment regimens and improved compliance. Despite these advances, last-generation nanosystems, such as targeted nanocarriers and hybrid systems, have still not been extensively explored in the field of trypanosomatid-caused conditions and represent promising opportunities for future developments. The potential use of nanotechnology in extended, well-tolerated drug regimens is particularly interesting in the light of recent descriptions of quiescent/dormant stages of Leishmania and Trypanosoma cruzi, which have been linked to therapeutic failure.
Fil: Muraca, Giuliana Sabrina. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Ministerio de Salud. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica; Argentina
Fil: Rivero Berti, Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Investigación y Desarrollo en Fermentaciones Industriales. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Investigación y Desarrollo en Fermentaciones Industriales; Argentina
Fil: Sbaraglini, Maria Laura. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
Fil: Fávaro, Wagner J.. Universidade Estadual Do Campinas. Instituto de Biologia. Departamento de Biologia Estructural y Funcional.; Brasil
Fil: Durán, Nelson. Universidade Estadual Do Campinas. Instituto de Biologia. Departamento de Biologia Estructural y Funcional.; Brasil. Universidad Federal do Abc; Brasil
Fil: Castro, Guillermo Raul. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Investigación y Desarrollo en Fermentaciones Industriales. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Investigación y Desarrollo en Fermentaciones Industriales; Argentina
Fil: Talevi, Alan. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
description Trypanosomatid-caused conditions (African trypanosomiasis, Chagas disease, and leishmaniasis) are neglected tropical infectious diseases that mainly affect socioeconomically vulnerable populations. The available therapeutics display substantial limitations, among them limited efficacy, safety issues, drug resistance, and, in some cases, inconvenient routes of administration, which made the scenarios with insufficient health infrastructure settings inconvenient. Pharmaceutical nanocarriers may provide solutions to some of these obstacles, improving the efficacy–safety balance and tolerability to therapeutic interventions. Here, we overview the state of the art of therapeutics for trypanosomatid-caused diseases (including approved drugs and drugs undergoing clinical trials) and the literature on nanolipid pharmaceutical carriers encapsulating approved and non-approved drugs for these diseases. Numerous studies have focused on the obtention and preclinical assessment of lipid nanocarriers, particularly those addressing the two currently most challenging trypanosomatid-caused diseases, Chagas disease, and leishmaniasis. In general, in vitro and in vivo studies suggest that delivering the drugs using such type of nanocarriers could improve the efficacy–safety balance, diminishing cytotoxicity and organ toxicity, especially in leishmaniasis. This constitutes a very relevant outcome, as it opens the possibility to extended treatment regimens and improved compliance. Despite these advances, last-generation nanosystems, such as targeted nanocarriers and hybrid systems, have still not been extensively explored in the field of trypanosomatid-caused conditions and represent promising opportunities for future developments. The potential use of nanotechnology in extended, well-tolerated drug regimens is particularly interesting in the light of recent descriptions of quiescent/dormant stages of Leishmania and Trypanosoma cruzi, which have been linked to therapeutic failure.
publishDate 2020
dc.date.none.fl_str_mv 2020-11-26
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/143293
Muraca, Giuliana Sabrina; Rivero Berti, Ignacio; Sbaraglini, Maria Laura; Fávaro, Wagner J.; Durán, Nelson; et al.; Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers; Frontiers Media; Frontiers in Chemistry; 8; 26-11-2020; 1-23
2296-2646
CONICET Digital
CONICET
url http://hdl.handle.net/11336/143293
identifier_str_mv Muraca, Giuliana Sabrina; Rivero Berti, Ignacio; Sbaraglini, Maria Laura; Fávaro, Wagner J.; Durán, Nelson; et al.; Trypanosomatid-caused conditions: State of the art of therapeutics and potential applications of lipid-based nanocarriers; Frontiers Media; Frontiers in Chemistry; 8; 26-11-2020; 1-23
2296-2646
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fchem.2020.601151/full
info:eu-repo/semantics/altIdentifier/doi/10.3389/fchem.2020.601151
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781377830191104
score 12.982451

Publicaciones similares